The panelists address the real-world barriers that continue to limit the use of PCSK9-targeting therapies in ASCVD care. Despite strong evidence supporting their efficacy and safety, the experts note that cost, insurance restrictions, and prior authorization delays remain the most significant obstacles to access. Many patients who qualify under current guidelines face long approval processes or denials, leading to treatment gaps and frustration for both patients and clinicians. The panel also highlights the burden on healthcare teams, who spend substantial time navigating paperwork and appeals. Even when access is granted, lack of awareness or familiarity among some clinicians can delay therapy initiation. The experts emphasize that broader education, simplified approval pathways, and improved affordability are essential to expanding use. They conclude that overcoming these administrative and systemic hurdles is critical to ensuring more patients benefit from potent LDL-C–lowering therapies proven to reduce recurrent ASCVD events.